Treatment and prognosis of idiopathic interstitial pneumonia

Thematic Poster
Chairs: J. Morisset (Montréal (QC), Canada), R. Pandey (kathmandu, Nepal), V. Vicens Zygmunt (Castelldefels (Barcelona), Spain), S. Guler (Bern, Switzerland)

Dedicated Pulmonary Rehabilitation for Patients with Interstitial Lung Disease in a District General Hospital N. Ramsundar (Luton, United Kingdom), T. Ingle (Luton, United Kingdom), D. Allen (Luton, United Kingdom), L. Drummond (Luton, United Kingdom)
Integrated education sessions included in a tailored rehabilitation program for patients with interstitial lung disease M. AlQuaimi (Dammam, Saudi Arabia), L. Mcneillie (Newcastle upon Tyne, United Kingdom), C. Donaldson (Newcastle upon Tyne, United Kingdom), J. Harper (Newcastle upon Tyne, United Kingdom), J. Hartley (Newcastle upon Tyne, United Kingdom), A. Simpson (Newcastle upon Tyne, United Kingdom), S. Cassidy (Newcastle upon Tyne, United Kingdom), A. Bourke (Newcastle upon Tyne, United Kingdom), C. Ward (Newcastle upon Tyne, United Kingdom), I. Forrest (Newcastle upon Tyne, United Kingdom)
Survival on antifibrotic therapy in IPF – the impact of pleural plaques, concomitant emphysema and definite vs possible UIP D. Anderson (Glasgow, United Kingdom), S. Briggs (Glasgow, United Kingdom), A. Mckay (Glasgow, United Kingdom), S. Mccluskey (Glasgow, United Kingdom), A. Wright (Glasgow, United Kingdom), G. Chalmers (Glasgow, United Kingdom)
The clinical efficacy of pulmonary hypertension-specific agents in idiopathic pulmonary fibrosis: A systematic review and meta-analysis M. Kim (Jeju, Republic of Korea), H. Jwa (Jeju, Republic of Korea)
Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients M. Sakayori (Chiba, Japan), J. Terada (Chiba, Japan), M. Abe (Chiba, Japan), K. Suzuki (Chiba, Japan), K. Yoshioka (Chiba, Japan), K. Tsushima (Narita, Japan), K. Tatsumi (Chiba, Japan)
What patients with IPF can expect concerning symptoms and quality of life during first six months of antifibrotic treatment? D. Jastrzebski (Zabrze, Poland), A. Gasiorek (Zabrze, Poland), D. Galczynska (Zabrze, Poland), S. Czyz (Zabrze, Poland), B. Ziaja (Zabrze, Poland), J. Warzecha (Zabrze, Poland), S. Kostorz-Nosal (Zabrze, Poland), D. Ziora (Zabrze, Poland)
Interstitial lung disease at a district general hospital: When are patients referred to tertiary care? M. Burton (Basildon, United Kingdom), K. Wadsworth (Basildon, United Kingdom)
Physical activity in idiopathic pulmonary fibrosis D. Badenes Bonet (Barcelona, Spain), D. Rodríguez Chiaradia (Barcelona, Spain), A. Rodó Pin (Barcelona, Spain), O. Caguana Vélez (Barcelona, Spain), J. Martínez Llorens (Barcelona, Spain), J. Gea Guiral (Barcelona, Spain), E. Balcells Vilarnau (Barcelona, Spain)
Aerobic and Breathing Exercises Improve Dyspnea, Exercise Capacity and Quality of Life in Idiopathic Pulmonary Fibrosis Patients: Systematic Review and Meta-Analysis. M. Hanada (Nagasaki, Japan), K. Kasawara (Toronto, Canada), S. Mathur (Toronto, Canada), D. Rozenberg (Toronto, Canada), R. Kozu (Nagasaki, Japan), D. Reid (Toronto, Canada)
Potential benefits of Nordic Walking for Idiopathic Pulmonary Fibrosis P. Trias Sabrià (Barcelona, Spain), C. Martin Cabeza (Barcelona, Spain), M. Sampere Aymerich (Barcelona, Spain), M. Tutusaus (Barcelona, Spain), J. Palma López (Barcelona, Spain), M. Molina-Molina (Barcelona, Spain), V. Vicens-Zygmunt (Barcelona, Spain)
What proportion of patients with Idiopathic Pulmonary Fibrosis fall outside UK prescribing criteria for anti-fibrotic treatment? A UK specialist centre review. C. Brereton (Southampton, United Kingdom), K. Pontoppidan (Southampton, United Kingdom), T. Wallis (Southampton, United Kingdom), L. Richeldi (Rome, Italy), M. Jones (Southampton, United Kingdom), S. Fletcher (Southampton, United Kingdom)
Impact of compliance and specialist nurse support on IPF survival in patients commenced on antifibrotic therapy D. Anderson (Glasgow, United Kingdom), S. Briggs (Glasgow, United Kingdom), S. Mccluskey (Glasgow, United Kingdom), A. Mckay (Glasgow, United Kingdom), A. Wright (Glasgow, United Kingdom), G. Chalmers (Glasgow, United Kingdom)
Idiopathic Pulmonary Fibrosis based on disease behavior: Workshop summary of a Japanese multicenter study Y. Inoue (Osaka, Japan), M. Akira (Osaka, Japan), T. Kasai (Osaka, Japan), T. Arai (Osaka, Japan), K. Tachibana (Osaka, Japan), C. Sugimoto (Osaka, Japan), N. Takeuchi (Osaka, Japan), Y. Matsui (Osaka, Japan), Y. Kawabata (JP, Japan), T. Johkoh (JP, Japan), F. Sakai (JP, Japan), R. Egashira (JP, Japan), H. Sumikawa (JP, Japan), S. Shimizu (JP, Japan), T. Tanaka (JP, Japan), T. Takemura (JP, Japan), S. Izumi (JP, Japan), K. Sakamoto (JP, Japan), S. Matsumoto (JP, Japan), K. Hatanaka (JP, Japan), G. Matama (JP, Japan), T. Baba (JP, Japan), R. Mori (JP, Japan), H. Tomioka (JP, Japan), K. Tomii (JP, Japan), N. Hamada (JP, Japan), N. Nagata (JP, Japan), Y. Kondoh (JP, Japan), K. Kataoka (JP, Japan), T. Kishaba (JP, Japan), Y. Nakamura (JP, Japan), A. Yamagata (JP, Japan), A. Tanaka (JP, Japan), V. Poletti (Forli, Italy), M. Kitaichi (Wakayama, Japan)
ORAL MORPHINE IS SAFE IN SYMPTOMATIC PATIENTS WITH FIBROTIC INTERSTITIAL LUNG DISEASES S. Kronborg-White (Aarhus, Denmark), C. Uggerhøj Andersen (Aarhus, Denmark), O. Hilberg (Vejle, Denmark), E. Bendstrup (Aarhus, Denmark)
MUC5B genotype affects survival of patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment D. Biondini (Padova, Italy), E. Balestro (Padova, Italy), C. Rigobello (Padova, Italy), S. Baraldo (Padova, Italy), D. Lacedonia (Foggia, Italy), E. Cocconcelli (Padova, Italy), E. Bazzan (Padova, Italy), M. Foschino Barbaro (Foggia, Italy), M. Cosio (Montreal, Canada), M. Saetta (Padova, Italy), P. Spagnolo (Padova, Italy)
Efficacy and safety of nintedanib in the elderly patient with IPF E. Bendstrup (Aarhus, Denmark), F. Bonella (Essen , Germany), E. Bargagli (Siena , Italy), W. Stansen (Ingelheim am Rhein , Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Orsatti (Ingelheim am Rhein, Germany), I. Glaspole (Melbourne, Victoria, Australia)
Safety and pharmacokinetics of nintedanib plus sildenafil in the INSTAGE trial U. Costabel (Essen, Germany), S. Shapera (Toronto, Ontario, Canada), S. Tomassetti (Forlì, Italy), T. Baba (Yokohama, Japan), B. Schinzel (Ingelheim am Rhein, Germany), S. Wiebe (Biberach, Germany), M. Quaresma (Ingelheim am Rhein, Germany), M. Kolb (Hamilton, Ontario, Canada)
Episodes of Acute Respiratory Deterioration in patients with idiopathic pulmonary fibrosis in the UK – mortality and contributing factors M. Marcus (Bracknell, United Kingdom), D. Clarke (Bracknell, United Kingdom), A. Tebboth (Bracknell, United Kingdom), P. Das (Bracknell, United Kingdom), S. Fletcher (Southampton, United Kingdom)
Change in 6-minute walk test can predict prognosis in idiopathic pulmonary fibrosis J. Gao (Stockholm, Sweden), D. Kalafatis (Stockholm, Sweden), I. Pesonen (Stockholm, Sweden), L. Carlson (Stockholm, Sweden), F. Giovanni (Stockholm, Sweden), M. Sköld (Stockholm, Sweden)